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Background
Co formulation enhance adherence in HIV infected
patients who initiate HAART. Aim of this study was to
compare the efficacy and safety of Atripla vs Truvada
plus Sustiva in naive HIV-infected patients.
Methods
This prospective and observational study was conducted
at a referral outclinic in Madrid. All consecutive patients
who initiated TDF+FTC+EFV coformulated (Atripla) as a
first regim were compared to patients who initiated TDF
+FTC (Truvada) plus EFV (Sustiva). Primary outcomes
were time to viral suppression and immune recovery,
assessed quarterly during regular follow up. Secondary
outcomes were classified as drug-related adverse events
and AIDS related events. Statistical analyses were realised
using the Chi-square and the T-student test for categori-
cal and continuous variables, respectively.
Results
The study population was composed by 33 patients
included in the cohort of patients treated by Atripla and
72 patients included in the cohort of patients treated by
Truvada plus Sustiva. In the Atripla cohort, mean age was
37,4 years, 97% were men, 46% were native Spaniards, 54%
were MSM and 6% had a HCV coinfection. In this cohort,
mean nadir CD4 count was 291 cells/μLa n dm e a nv i r a l
load at baseline was 4,3 log. All variables were similarly
distributed in both cohorts except for liver stiffness: 18%
had a F4 Metavir score in the Atripla group and any case
at this stage was reported in the Truvada+Sustiva group.
RT sequencing was available at baseline for 67% in
patients initiating Atripla and for 75% in the other group.
No major mutations were found and distribution was
similar for minor mutations. All patients in both groups
achieved viral suppression but time was inferior in the
Atripla group (2,7 months vs 4,5, p < 0,005) and CD4
recovery was superior; 163 vs 148 (p < 0,005). In both
groups, 15% of patients presented CNS-related adverse
events. It is noteworthy that one patient treated by Tuvada
plus Sustiva presented overdose of EFV.
Discussion
In current clinical practice, TDF+FTC+EFV coformu-
lated was as effective and safe as TDF+FTC and EFV.
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